Charles N Bernstein1, Carol A Hitchon1, Randy Walld2, James M Bolton3, Jitender Sareen3, John R Walker4, Lesley A Graff4, Scott B Patten5, Alexander Singer6, Lisa M Lix2,7, Renée El-Gabalawy8,5, Alan Katz2,6,7, John D Fisk8,9,10,11, Ruth Ann Marrie1,6. 1. Department of Internal Medicine, MB, Canada. 2. Manitoba Centre for Health Policy, MB, Canada. 3. Department of Psychiatry, MB, Canada. 4. Department of Clinical Health Psychology, MB, Canada. 5. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 6. Department of Family Medicine, MB, Canada. 7. Department of Community Health Sciences, MB, Canada. 8. Department of Anesthesia and Perioperative Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 9. Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. 10. Department of Psychology and Neuroscience, Dalhousie University, Halifax, NS, Canada. 11. Department of Medicine, Dalhousie University, Halifax, NS, Canada.
Abstract
Background: Psychiatric comorbidity in inflammatory bowel disease (IBD) is well known; however, data from a truly representative sample are sparse. We aimed to estimate the incidence and prevalence of psychiatric disorders in an IBD cohort compared with a matched cohort without IBD. Methods: Using population-based administrative health data from Manitoba, Canada, we identified all persons with incident IBD from 1989 to 2012 and a general population matched cohort (5:1). We applied validated algorithms for IBD, depression, anxiety disorders, bipolar disorder, and schizophrenia to determine the annual incidence of these conditions post-IBD diagnosis and their lifetime and current prevalence. Results: There were 6119 incident cases of IBD and 30,573 matched individuals. After adjustment for age, sex, socioeconomic status, region of residence, and year, there was a higher incidence in the IBD cohort compared with controls for depression (incidence rate ratio [IRR], 1.58; 95% confidence interval [CI], 1.41-1.76), anxiety disorder (IRR, 1.39; 95% CI, 1.26-1.53), bipolar disorder (IRR, 1.82; 95% CI, 1.44-2.30), and schizophrenia (IRR, 1.64; 95% CI, 0.95-2.84). Incidence rate ratios were similar for Crohn's disease and ulcerative colitis between males and females and were stable over time. However, within the IBD cohort, the incidence rates of depression, anxiety, and bipolar disorders were higher among females, those aged 18-24 years vs those older than 44 years, urbanites, and those of lower socioeconomic status. The lifetime and current prevalence rates of psychiatric disorders were also higher in the IBD than the matched cohort. Conclusions: The incidence and prevalence of psychiatric disorders are elevated in the IBD population.
Background: Psychiatric comorbidity in inflammatory bowel disease (IBD) is well known; however, data from a truly representative sample are sparse. We aimed to estimate the incidence and prevalence of psychiatric disorders in an IBD cohort compared with a matched cohort without IBD. Methods: Using population-based administrative health data from Manitoba, Canada, we identified all persons with incident IBD from 1989 to 2012 and a general population matched cohort (5:1). We applied validated algorithms for IBD, depression, anxiety disorders, bipolar disorder, and schizophrenia to determine the annual incidence of these conditions post-IBD diagnosis and their lifetime and current prevalence. Results: There were 6119 incident cases of IBD and 30,573 matched individuals. After adjustment for age, sex, socioeconomic status, region of residence, and year, there was a higher incidence in the IBD cohort compared with controls for depression (incidence rate ratio [IRR], 1.58; 95% confidence interval [CI], 1.41-1.76), anxiety disorder (IRR, 1.39; 95% CI, 1.26-1.53), bipolar disorder (IRR, 1.82; 95% CI, 1.44-2.30), and schizophrenia (IRR, 1.64; 95% CI, 0.95-2.84). Incidence rate ratios were similar for Crohn's disease and ulcerative colitis between males and females and were stable over time. However, within the IBD cohort, the incidence rates of depression, anxiety, and bipolar disorders were higher among females, those aged 18-24 years vs those older than 44 years, urbanites, and those of lower socioeconomic status. The lifetime and current prevalence rates of psychiatric disorders were also higher in the IBD than the matched cohort. Conclusions: The incidence and prevalence of psychiatric disorders are elevated in the IBD population.
Authors: Juliette M Mott; Kathleen M Grubbs; Shubhada Sansgiry; John C Fortney; Jeffrey A Cully Journal: J Rural Health Date: 2014-12-03 Impact factor: 4.333
Authors: Sheldon Cohen; Denise Janicki-Deverts; William J Doyle; Gregory E Miller; Ellen Frank; Bruce S Rabin; Ronald B Turner Journal: Proc Natl Acad Sci U S A Date: 2012-04-02 Impact factor: 11.205
Authors: Addie Weaver; Joseph A Himle; Robert Joseph Taylor; Niki N Matusko; Jamie M Abelson Journal: JAMA Psychiatry Date: 2015-06 Impact factor: 21.596
Authors: Sunny Singh; Andrea Blanchard; John R Walker; Lesley A Graff; Norine Miller; Charles N Bernstein Journal: Clin Gastroenterol Hepatol Date: 2011-05-20 Impact factor: 11.382
Authors: Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler Journal: Arch Gen Psychiatry Date: 2007-05
Authors: Michał Łodyga; Piotr Eder; Magdalena Gawron-Kiszka; Agnieszka Dobrowolska; Maciej Gonciarz; Marek Hartleb; Maria Kłopocka; Ewa Małecka-Wojciesko; Piotr Radwan; Jarosław Reguła; Edyta Zagórowicz; Grażyna Rydzewska Journal: Prz Gastroenterol Date: 2021-11-19
Authors: Charles N Bernstein; Carol A Hitchon; Randy Walld; James M Bolton; Lisa M Lix; Renée El-Gabalawy; Jitender Sareen; Alexander Singer; Alan Katz; James Marriott; John D Fisk; Scott B Patten; Ruth Ann Marrie Journal: Inflamm Bowel Dis Date: 2021-08-19 Impact factor: 5.325
Authors: Haley A Vecchiarelli; Maria Morena; Catherine M Keenan; Vincent Chiang; Kaitlyn Tan; Min Qiao; Kira Leitl; Alessia Santori; Quentin J Pittman; Keith A Sharkey; Matthew N Hill Journal: Neuropsychopharmacology Date: 2021-01-15 Impact factor: 7.853